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Bisphosphonates are widely used to prevent osteoporotic fractures. Some severe musculo-
skeletal reactions have been described with this medication; among them, some cases of
carpal tunnel syndrome. Thus, the aim of this study was to explore whether bisphospho-
nates may be associated with this syndrome.
Methods
A cohort study was conducted to compare exposed to unexposed women; the exposed
group was that composed of women having received at least one prescription of an oral bis-
phosphonate. For the purpose, we used information from The Health Improvement Network
(THIN) database. The outcome of interest was defined as those women diagnosed with car-
pal tunnel syndrome. A survival analysis was performed; the Cox proportional hazard
model was used to calculate hazard ratios and 95% confidence intervals, and to adjust for
identified confounding variables.
Results
Out of a sample of 59,475 women older than 51 years, 19,825 were treated with bisphos-
phonates during the period studied. No differences in age distribution or mean follow-up
time were observed between the two groups in comparison. Overall, there were 572 women
diagnosed with carpal tunnel syndrome, 242 (1.2%) in the group exposed to bisphospho-
nates, and 330 (0.8%) in the unexposed. An adjusted hazard ratio of developing carpal tun-
nel syndrome of 1.38 (95%CI, 1.15–1.64) was found for women exposed to
bisphosphonates; no significant changes in the hazard ratios were found when considering
different levels of bisphosphonate exposure.
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Conclusions
An increased risk of carpal tunnel syndrome is associated with the use of bisphosphonates
in postmenopausal women.
Background
Bisphosphonates have proven to avoid osteoporotic fractures and are widely used to prevent
these fractures particularly in postmenopausal women [1]. Prevalence of bisphosphonate use
has considerably increased in the last years, due in part to demographic trends in older female
population and to concerns of Hormone Replacement Therapy safety [2]. However, concerns
have also been raised about serious adverse effects of this medication; these include osteonecro-
sis of the jaw, atrial fibrillation, atypical fractures [3] and, recently, conflicting evidence regard-
ing risk of esophageal cancer [4]. Besides, a link between taking bisphosphonates and a raised
risk of severe musculoskeletal pain has been established [5, 6]; indeed, prescribing information
for all bisphosphonates already includes warnings of this particular risk [7, 8]. Additionally,
cases of synovitis, a well-recognized cause of carpal tunnel syndrome (CTS) (acting through
increased local pressure), have occasionally been reported [9–11].
CTS is the commonest peripheral nerve condition and has considerable employment and
healthcare costs [12]; it is caused by elevated pressure in the carpal tunnel, and this in turn pro-
duces compression of the median nerve, resulting in impaired nerve conduction, paresthesia
and pain [13]. The role of occupation has been the focus of much attention as a possible risk
factor [14]. In a study carried out with a twin registry in the UK, a genetic predisposition was
found to be the single strongest factor in predicting CTS [15]; BMI increase has also been con-
sistently identified as a risk factor [16, 17]. Other medications such as lithium [18], oral contra-
ceptives [19], exemestene [20]—an aromatase inhibitor used to treat breast cancer—and
dabigatran [21] have occasionally been involved in CTS. The aim of this study was to explore
whether bisphosphonates may be associated with carpal tunnel syndrome.
Methods
Design and setting
We conducted a retrospective cohort study by using data from The Health Improvement Net-
work (THIN) database (www.thin-uk.com). This is a large database of anonymized computer-
ized primary health care records of patients throughout the UK; it contains the electronic
clinical records of more than 9.1 million patients (3.4 million of whom are alive). Anonymized
patients’ data are collected from over 479 participating practices that are broadly representative
of UK general practices in terms of patients’ age and sex, practice size, and geographical distri-
bution [22]; moreover, consultation and prescription rates recorded in the THIN database
have been shown to be comparable with published estimates [23]. Every prescription issued by
the general practitioner, all consultations with the general practitioner, test results and diagno-
ses from primary and secondary care, referrals to outpatient clinics, hospital admissions, and
deaths are coded by the general practitioner and entered into the database, as are basic demo-
graphic data and certain lifestyle data, such as smoking status and alcohol intake; recorded
diagnoses and symptoms are classified using Read codes [24]. The THIN database has been
validated for pharmacoepidemiological research [25].
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Study population
Our study population was based on women over 51 years registered for 1 year between 09/
25/1994 and 07/07/2005 with records in the THIN database. Patients diagnosed with cancer or
Paget’s disease, or registered for less than 1 year with their GP, were excluded.
Exposure, index date and matching
In our cohort study we compared exposed to unexposed women; the exposed group was that
composed of women having received at least one prescription of an oral bisphosphonate, i.e.,
they had a record of at least one prescription for any oral bisphosphonate preparation that is
licensed in the UK for use in osteoporosis (British National Formulary section 6.6.2: sodium
clodronate, disodium etidronate, and the aminobisphosphonates: alendronic acid, ibandronic
acid and risedronate sodium); thus, IV bisphosphonates, such as zolendronic acid, whose main
use was to treat bone metastases induced-fractures were not included. The date of the first pre-
scription was the index date for exposed, and matched to the same date for the corresponding
unexposed individuals; for every treated woman, two unexposed women, matched by age of
treated woman at the index date, were taken as controls; exposed and unexposed women were
also matched by practice, and any individual with previous history of carpal tunnel syndrome
prior to bisphosphonate drug exposure was excluded from the analysis.
Level of Exposure
Exposure was primarily defined as any exposure to bisphosphonates. Subsequently, the num-
ber of prescriptions issued was considered; it was stratified in 3 categories according to inten-
sity of prescribing (number of prescriptions: 1–4, 5–16 and more than 16).
Outcome
The outcome of interest was defined as those women diagnosed with CTS; women were
defined as having CTS if, at any time during the observation period, they had a medical record
of the syndrome (Read codes: F340.00—carpal tunnel syndrome; 7056400—endoscopic carpal
tunnel release; 85BE.00—injection of carpal tunnel; 7056000—carpal tunnel release; 7056011—
carpal tunnel decompression; 7056200 –re-release of carpal tunnel). The date of the first
recorded code was considered the diagnosis date. A sensitivity analysis examined solely surgical
related codes such as: endoscopic carpal tunnel release, carpal tunnel release, carpal tunnel
decompression and re-release of carpal tunnel.
Covariates
Based on the literature, covariates initially considered for adjusting in the analysis were: age,
smoking status, alcohol intake, BMI, hypothyroidism, rheumatoid arthritis, all types of diabetes
and number of GP visits over a defined time period. The information taken was that consigned
closest to the index date; for the visits to the GP, the number was that within three months pre-
vious to the index date. Confounders were selected among those with a p<0.1 significance level
in a previous univariable analysis. A forward stepwise method was applied to select confound-
ers to be included in the final multivariable model.
Statistical analysis
For survival analysis, the Cox proportional hazard model was used to calculate hazard ratios
(HRs) and 95% CIs, and to adjust for identified confounding variables.
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Risks were examined by category of bisphosphonate (amino- versus non aminobisphospho-
nate) and, where numbers permitted, by individual drug. Patients who were transferred out of
the general practice or who died were censored, and the date of the censoring event was used as
the end of follow-up time. To address missing values in the Cox regression analysis, multiple
imputation method was performed; other for sensitivity analysis methods were also used, a
complete-subject analysis, and the creation of a missing data category. We included interaction
terms between exposure and each of the categorical variables considered; interaction terms
between exposure and duration of follow-up was used to test the proportional hazard assump-
tion, and the assumption was not shown to be violated (P>0.05 for all tests). To investigate
dose response, separate analyses were conducted for the three categories established (1–4; 5–16
and> 16); each exposed group was compared with the corresponding matched unexposed
group.
All analyses were conducted using SPSS software, version 19.0 (licenced for Universidad de
Valladolid, 2013), and tests were performed at the 5% significance level.
Results
Out of a sample of 59,475 women older than 51 years, 19,825 were treated with bisphospho-
nates during the period studied; this accounts for an exposed cohort of 51,245 person-years of
follow-up. Distribution of prognostic factors between exposed and unexposed women after
matching is presented in Table 1. No differences in age distribution or mean follow-up time
were observed between the two groups in comparison. Overall, there were 572 women diag-
nosed with carpal tunnel syndrome, 242 (1.2%) in the group exposed to bisphosphonates, and
330 (0.8%) in the unexposed. An adjusted hazard ratio of developing carpal tunnel syndrome
of 1.38 (95%CI, 1.15–1.64) was found for women exposed to bisphosphonates (Table 2); simi-
lar results were found when applying other methods to deal with missing values—complete
subject analysis and missing data as a category. No significant changes in the hazard ratios
were found when considering the levels of bisphosphonates exposure (Table 2). When consid-
ering those CTS codes referred to surgical procedures, the numbers of cases of CTS were 85
(0.4%) in the group exposed to bisphosphonates, and 115 (0.3%) in the unexposed; the crude
and adjusted hazard ratios were, 1.49 (95%CI, 1.12–1.97) and 1.48 (95%CI, 1.09–2.00), respec-
tively. Women exposed to aminobisphosphonates did not present a higher risk of CTS;
adjusted hazard ratios of aminobisphosphonate-treated women (n = 15639) versus unexposed
women and non-aminobisphosphonate-treated women (n = 2281) versus unexposed women
were 1.36 (95%CI, 1.11–1.66) and 1.37 (95%CI, 0.95–1.96), respectively. For women exposed
to alendronate (n = 11563), the most widely used bisphosphonate, the adjusted hazard ratio of
CTS was 1.34 (95%CI, 1.08–1.65).
A higher BMI was independently associated with a higher risk of CTS; adjusted hazard
ratios for BMI 25.0–29.9 versus BMI<25 and BMI>30 versus BMI<25 were 1.28 (95%CI,
1.06–1.59) and 1.80 (95%CI, 1.46–2.23), respectively. No statistically significant relationship
was found between diabetes, hypothyroidism or rheumatoid arthritis and risk of CTS after con-
trolling for other risk factors.
Discussion
In this cohort study with prospectively recorded information on prescribing of bisphospho-
nates, we found a statistically significant increased risk of CTS in women over 51 years of age
treated with oral bisphosphonates. The risk was not related to the level of drug exposure, nor
has it varied with the class of bisphosphonate used, whether amino- or non-aminobisphospho-
nate or even specific bisphosphonates such as alendronate. Our study was able to clearly
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confirm higher BMI as an independent risk factor for CTS; a higher BMI has been similarly
identified in most of the observational studies upon CTS [16, 17]. However, though women
with the highest BMIs are more likely to develop CTS, they are less prone to develop osteopo-
rosis and subsequently less prone also to receive a bisphosphonate prescription; in fact, in our
cohort, a lower percentage of women with the highest BMIs received bisphosphonate prescrip-
tions (46% and 34% of women having BMI 25.0–29.9 and BMI>30 received bisphosphonate
prescriptions, respectively, versus 68% for those having BMI<25). In our analysis comprising
women whose median age was 72 years-old we did not observe diabetes, hypothyroidism and
rheumatoid arthritis as significant risk factors for CTS; this is consistent with what has recently
been observed in a large case-control study [26], aging appears to reduce the relative impact of
the diseases commonly associated with CTS as the possible risk factors.
Table 1. Baseline characteristics. Distribution according to prognostic factors.
Number (%)
Exposed (n = 19 825) Unexposed (n = 39 650)
Age at Index Date (mean ± SD), years 72.1 ± 10.0 72.1 ± 10.0
<59 2647 (13.5) 5294 (13.4)
60–69 5134 (25.9) 10 269 (25.9)
70–89 11 402 (57.5) 22 800 (57.5)
90 642 (3.2) 1287 (3.3)
Follow-up (mean ± SD), years a 2.6 ± 1.9 2.6 ± 1.9
Number of GP visits (mean ± SD)b 4.3 (3.8) 2.2 (2.9)
<2 4829 (24.4) 21 323 (53.8)
2–4 7582 (38.2) 12 368 (31.2)
5 7414 (37.4) 5959 (15.0)
Alcohol intake
Non-heavy drinker 18 064 (91.1) 36 537 (92.1)
Heavy drinker 1728 (8.7) 3051 (7.7)
Missingc 33 (0.12) 62 (0.2)
BMI (kg/m2)
<25.0 8974 (45.3) 13 117 (33.1)
25.0–29.9 5138 (25.9) 11 256 (28.4)
30 2317 (11.7) 6839 (17.2)
Missing 3396 (17.1) 8438 (21.3)
Smoking status
Never 5865 (29.6) 11 429 (28.8)
Former 6027 (30.4) 11 734 (29.6)
Current 6387 (32.2) 11 928 (30.1)
Missing 1546 (7.8) 4559 (11.5)
Diabetes 3104 (15.7) 4774 (12.0)
Hypothyroidism 2139 (10.8) 3534 (8.9)
Rheumatoid Arthritis 1315 (6.6) 642 (1.6)
a Time from Index Date to outcome or censorship
b Visits within three months prior to Index Date
c Heavy drinker recorded when the patient ever has a heavy drinker record (speciﬁc Read code or
condition consistent with heavy alcohol consumption) and non-heavy drinker otherwise. When there was no
consistent information to ascribe the case to one of the previous categories, data were considered as
missing.
doi:10.1371/journal.pone.0146772.t001
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An alert highlighting the possibility of severe and sometimes incapacitating bone, joint,
and/or musculoskeletal pain has been issued by the FDA [27]; indeed, prescription information
for all bisphosphonates includes warnings of this particular risk [7, 8]. This severe musculo-
skeletal pain may occur within days, months or years after starting bisphosphonates. A series
of 117 cases of severe musculoskeletal pain developing in adults on bisphosphonates has been
published [5]. Moreover, cases of synovitis confirmed by positive re-challenge have also been
reported [9–11] and may occur at any point after starting bisphosphonate therapy, similarly to
the occurrence of the cases of CTS we identified.
Arthritis—one of the leading causes of CTS [10]—and its correlate arthralgia is one of the
most reported adverse effects for bisphosphonates. Two facts would be able to explain biologi-
cal plausibility of bisphosphonate-induced arthritis and synovitis. First, the appearance of
inflammatory cytokines, in particular TNFα and IL6, has been observed after bisphosphonate
treatment in vitro and in patients [28–31]; thus, for synovitis to occur, synovial macrophages
would release those cytokines when bisphosphonates are present; the way this process is trig-
gered remains unclear. Second, the skeletal half-life of various bisphosphonates is sometimes
more than 10 years [32]; once bisphosphonates are buried in the skeleton, they will be released
only when the bone is destroyed in the course of turnover. Being an inflammatory process
which can be triggered by these substances in any moment during long periods would explain
the fact that this reaction is not related to time or dose.
The strengths of the present study are its large sample size, the long period of follow-up,
and the use of recorded prescription data rather than self-reported drug use, which may mis-
classify exposure.
Since bisphosphonates cannot be obtained without prescription in the United Kingdom,
underestimation of its usage would seem unlikely; however, a limitation of the study is that
drug adherence is unknown. In fact, since exposure does rely on prescriptions issued, overesti-
mation of usage is possible, as compliance with bisphosphonate prescribing is known to be sub-
optimal [33]); if so, the real CTS risk associated with bisphosphonates would be higher.
Additionally, an interval between prescription and intake might exist; however this informa-
tion is unknown for the two compared groups. Also, we relied on relevant diagnostic codes
from patients’ clinical files and CTS is a specialist diagnosis. However, as codes have a certain
degree of unreliability, some misclassification might be inevitable; therefore, we considered
those codes involving CTS surgical procedures which further supported the accuracy of the
diagnoses—most surgical procedures would also require electrophysiological testing, although
Table 2. Hazard of carpal tunnel syndrome associated with the intake of bisphosphonates.
Exposed Unexposed HR (95% CI)
Cases Person-years Cases Person-years Crude a Adjusted b, c
Any prescription 242 51 674 330 103 905 1.48 (1.25–1.75) 1.38 (1.15–1.64)
Number of prescriptions
1–4 46 10 568 83 25 843 1.37 (0.96–1.97) 1.29 (0.88–1.89)
5–16 73 14 860 98 31 134 1.54 (1.13–2.08) 1.34 (0.97–1.84)
17 123 26 246 149 46 928 1.47 (1.16–1.87) 1.43 (1.11–1.85)
a Adjusted for age-group (52–59, 60–69, 70–89, 90)
b Adjusted for BMI (<25, 25–29.9, 30), age-group (52–59, 60–69, 70–89, 90) and number of visits (<2, 2–4, 5)
c -2 log likelihood, p<0.0001 for all models
doi:10.1371/journal.pone.0146772.t002
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this is not routinely recorded in the notes—, finding no significant changes in our previous esti-
mates. Furthermore, the treatment of missing data for BMI, the only important variable with a
considerable number of missing data, was handled using the current recommended approaches
to avoid the biases that occur when omitting individuals with incomplete data. We were not
able to adjust for vocational activities as data was incomplete similarly data for chronic kidney
disease was sparsely recorded; although we have adjusted for the number of visits, it is still pos-
sible, but unlikely, as a surveillance bias.
In summary, we have identified an increased risk of CTS associated with bisphosphonates;
it is a novel finding with potential clinical impact. As increasing numbers of individuals, partic-
ularly postmenopausal women, are exposed to this medication, a large number of cases of this
invalidating and costly condition might appear in excess. If confirmed, doctors should be
aware to avoid prescribing this medication in those women with other risk factors for CTS
such as elevated BMI or family history of the disease; regulatory authorities, in turn, should
consider appropriate further safety advice regarding CTS risks with bisphosphonates.
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